His bundle pacing therapy for patients with chronic heart failure: a protocol for meta-analysis based on prospective studies

His-bundle pacing (HBP) appears to be a viable stand-alone or adjunctive physiological pacing therapy in pacemaker dependent patients. It could also serve as an effective adjunct or alternative pacing therapy for heart failure patients who require cardiac resynchronization therapy or pacemaker upgrade. His-bundle pacing has demonstrated improvement of His-Purkinje conduction, left ventricular electrical / mechanical synchronization, and left ventricular ejection fraction (LVEF) compared with right ventricle pacing. Patients who have high pacing dependence and/or LVEF impairment would benefit most from HBP in terms of heart failure hospitalization and LVEF improvement. Mortality benefit has not been consistently demonstrated in latest meta-analysis. The long-term clinical benefit and safety profile of HBP remains to be explored in future studies. Key words: His bundle pacing, physiologic pacing, upgrade pacing

Download Full-text

453 ExTraMATCH: exercise training meta analysis of trials in chronic heart failure patients. Reduction in mortality and hospitalization

European Journal of Heart Failure Supplements ◽

10.1016/s1567-4215(04)90325-6 ◽

2004 ◽

Vol 3 (1) ◽

pp. 114-115

Author(s):

M PIEPOLI

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Exercise Training ◽

Meta Analysis ◽

Heart Failure Patients

Download Full-text

Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): a meta-analysis

Minerva Cardioangiologica ◽

10.23736/s0026-4725.17.04382-1 ◽

2018 ◽

Vol 66 (5) ◽

Cited By ~ 3

Author(s):

Renato De Vecchis ◽

Arturo Cesaro ◽

Carmelina Ariano

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Meta Analysis ◽

Phosphodiesterase Inhibition ◽

Differential Effects

Download Full-text

Faculty Opinions recommendation of Impact of Frailty on Mortality and Hospitalization in Chronic Heart Failure: A Systematic Review and Meta-Analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734667335.793554598 ◽

2018 ◽

Author(s):

Davide Cattano

Keyword(s):

Heart Failure ◽

Systematic Review ◽

Chronic Heart Failure ◽

Meta Analysis

Download Full-text

Long-Term and Short-Term Prognostic Value of Circulating Soluble Suppression of Tumorigenicity-2 Concentration in Chronic Heart Failure: A Systematic Review and Meta-Analysis

Cardiology ◽

10.1159/000509660 ◽

2021 ◽

pp. 1-8

Author(s):

Guoqi Dong ◽

Hao Chen ◽

Hongru Zhang ◽

Yihuang Gu

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Prognostic Value ◽

Web Of Science ◽

Meta Analysis ◽

Short Term ◽

Prisma Statement ◽

All Cause Mortality ◽

Increasing Risk

Introduction: Soluble suppression of tumorigenicity-2 (sST2) has been considered as a prognostic factor of cardiovascular disease. However, the prognostic value of sST2 concentration in chronic heart failure remains to be summarized. Methods: We searched PubMed, Embase, and Web of Science for eligible studies up to January 1, 2020. Data extracted from articles and provided by authors were used in agreement with the PRISMA statement. The endpoints were all-cause mortality (ACM), cardiovascular mortality (CVM)/heart failure-related hospitalization (HFH), and all-cause mortality (ACM)/heart failure-related readmission (HFR). Results: A total of 11 studies with 5,121 participants were included in this analysis. Higher concentration of sST2 predicted the incidence of long-term ACM (hazard ratio [HR]: 1.03, 95% confidence interval [CI]: 1.02–1.04), long-term ACM/HFR (HR: 1.42, CI: 1.27–1.59), and long-term CVM/HFH (HR: 2.25, CI: 1.82–2.79), regardless of short-term ACM/HFR (HR: 2.31, CI: 0.71–7.49). Conclusion: Higher sST2 concentration at baseline is associated with increasing risk of long-term ACM, ACM/HFR, and CVM/HFH and can be a tool for the prognosis of chronic heart failure.

Download Full-text